American Healthcare REIT, Inc. (AHR)
(Delayed Data from NYSE)
$21.01 USD
+0.73 (3.60%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $21.00 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
American Healthcare REIT (AHR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$17.56 | $27.00 | $14.00 | -13.41% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for American Healthcare REIT comes to $17.56. The forecasts range from a low of $14.00 to a high of $27.00. The average price target represents a decline of 13.41% from the last closing price of $20.28.
Analyst Price Targets (9 )
Broker Rating
American Healthcare REIT currently has an average brokerage recommendation (ABR) of 1.61 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.61 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, five are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 55.56% and 22.22% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 22.22%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AHR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Colliers Securities | Barry Oxford | Hold | Hold |
8/7/2024 | JMP Securities | Aaron Hecht | Strong Buy | Strong Buy |
7/1/2024 | Truist Securities | Michael Lewis | Strong Buy | Strong Buy |
3/14/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/4/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
3/4/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Strong Buy | Strong Buy |
3/4/2024 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.61 |
ABR (Last week) | 1.61 |
# of Recs in ABR | 9 |
Average Target Price | $18.11 |
LT Growth Rate | 6.60% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | 0.31 |